First Hawaiian Bank Buys 15,987 Shares of GSK plc (NYSE:GSK)

First Hawaiian Bank increased its holdings in GSK plc (NYSE:GSK - Free Report) by 18.8% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 101,039 shares of the pharmaceutical company's stock after purchasing an additional 15,987 shares during the period. First Hawaiian Bank's holdings in GSK were worth $3,914,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP increased its position in GSK by 10.0% during the 4th quarter. Wellington Management Group LLP now owns 2,094,105 shares of the pharmaceutical company's stock valued at $70,823,000 after purchasing an additional 190,047 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in GSK by 8.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 174,688 shares of the pharmaceutical company's stock valued at $5,908,000 after purchasing an additional 13,039 shares during the period. Northstar Financial Companies Inc. purchased a new position in GSK during the 4th quarter valued at $228,000. Aegis Wealth Management LLC purchased a new position in GSK during the 4th quarter valued at $286,000. Finally, Probity Advisors Inc. increased its position in GSK by 58.8% during the 4th quarter. Probity Advisors Inc. now owns 15,120 shares of the pharmaceutical company's stock valued at $511,000 after purchasing an additional 5,599 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Up 2.6%

GSK stock traded up $1.03 during trading on Friday, hitting $41.03. 7,371,682 shares of the stock traded hands, compared to its average volume of 4,872,127. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.01. The firm's 50 day moving average is $37.33 and its two-hundred day moving average is $36.15. The stock has a market cap of $84.65 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same period in the prior year, the firm posted $0.43 EPS. GSK's revenue for the quarter was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a yield of 4.11%. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio is 86.60%.

Analyst Ratings Changes

A number of analysts have recently weighed in on GSK shares. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday. BNP Paribas started coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Finally, Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.